Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Inhibrx, Inc. (INBX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/07/2023 |
8-K
| Quarterly results |
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 05/25/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/08/2023 |
8-K
| Quarterly results |
| 05/08/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/26/2023 |
8-K
| Quarterly results |
| 04/13/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/13/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/06/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/06/2023 |
8-K
| Quarterly results |
| 03/06/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/02/2023 |
4
| Eckelman Brendan P. (Chief Scientific Officer) has filed a Form 4 on Inhibrx, Inc.|
Txns:
| Sold 39,600 shares
@ $24.2007, valued at
$958.3k
Sold 400 shares
@ $24.7075, valued at
$9.9k
|
|
| 03/01/2023 |
4
| Lappe Mark (CEO) has filed a Form 4 on Inhibrx, Inc.|
Txns:
| Sold 60 shares
@ $25.0208, valued at
$1.5k
|
|
| 02/14/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 8.9% stake in INHIBRX, INC. |
| 02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 7.6% stake in Inhibrx, Inc. |
| 02/14/2023 |
SC 13G/A
| VIKING GLOBAL INVESTORS LP reports a 15.2% stake in Inhibrx, Inc. |
| 02/08/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/03/2023 |
SC 13G
| BlackRock Inc. reports a 5.5% stake in Inhibrx, Inc. |
| 02/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/24/2023 |
4
| Lappe Mark (CEO) has filed a Form 4 on Inhibrx, Inc.|
Txns:
| Sold 21,665 shares
@ $25.3572, valued at
$549.4k
Sold 4,272 shares
@ $25.71, valued at
$109.8k
Sold 63 shares
@ $26.1127, valued at
$1.6k
|
|
| 01/23/2023 |
4
| Kayyem Jon Faiz (Director) has filed a Form 4 on Inhibrx, Inc.|
Txns:
| Sold 9,500 shares
@ $25.2631, valued at
$240k
|
|
| 01/04/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/22/2022 |
4
| Kayyem Jon Faiz (Director) has filed a Form 4 on Inhibrx, Inc.|
Txns:
| Sold 7,541 shares
@ $26.8653, valued at
$202.6k
Sold 1,959 shares
@ $27.6099, valued at
$54.1k
|
|
| 12/20/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/07/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/22/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/18/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/16/2022 |
8-K
| Quarterly results |
| 11/07/2022 |
8-K
| Quarterly results |
| 11/07/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/26/2022 |
8-K
| Quarterly results |
|
|
|